Skip to main content
. 2020 Apr 13;130(5):2560–2569. doi: 10.1172/JCI132712

Figure 1. Clinical trial profile and treatment schedule.

Figure 1

(A) Clinical trial profile. In total, 379 patients were selected for enrollment, 249 (65.7%) of whom were assessed for PD-L1 expression. For the 186 (74.7%) PD-L1+ patients, 78 (31.3%) had PD-L1 expression on at least 50% of their tumor cells. The PD-L1+ patients were screened for the eligibility criteria, and 109 (58.6%) were enrolled in the study and randomly assigned to group A or B. (B) Clinical treatment schedule. Patients in group A received pembrolizumab plus 1–3 courses of allogeneic NK cells; 1 NK cell treatment course was designed to contain 2 cycles, totaling 6 NK cell infusions in 28 days, i.e., days 12, 13, and 14 for the first cycle and days 26, 27, and 28 for the second cycle. Patients in group B received regular therapy with i.v. injection of pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, and the treatment was continued until disease progression or unacceptable toxicity occurred. n = 109.